Recurrence-free survival and prognostic factors in resected pN2 non-small cell lung cancer

By Choi Y.S.   Shim Y.M.   Kim J.   Kim K.  

European Journal of Cardio-Thoracic Surgery, Vol. 22, Iss. 5, 2002-11 ,pp. : 695-700

Elsevier

Access to resources Recommend Favorite

Prognostic prediction of the immunohistochemical expression of p53 and p16 in resected non-small cell lung cancer

By Cheng Y.-L.   Lee S.-C.   Harn H.-J.   Chen C.-J.   Chang Y.-C.   Chen J.-C.   Yu C.-P.  

European Journal of Cardio-Thoracic Surgery, Vol. 23, Iss. 2, 2003-02 ,pp. : 221-228

Elsevier

Access to resources Recommend Favorite

Advantage of post-operative oral administration of UFT (Tegafur and Uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC)

By Tanaka F.   Miyahara R.   Ohtake Y.   Yanagihara K.   Fukuse T.   Hitomi S.   Wada H.  

European Journal of Cardio-Thoracic Surgery, Vol. 14, Iss. 3, 1998-09 ,pp. : 256-262

Elsevier

Access to resources Recommend Favorite

Advantage of postoperative oral administration of UFT (Tegafur and Uracil) for completely resected p-Stage I-IIIa non-small cell lung cancer (NSCLC)

By Maggi G.   Ruffini E.  

European Journal of Cardio-Thoracic Surgery, Vol. 14, Iss. 3, 1998-09 ,pp. : 263-264

Elsevier

Access to resources Recommend Favorite

Microscopic (R1) and macroscopic (R2) residual disease in patients with resected non-small cell lung cancer

By Hofmann H.S.   Taege C.   Lautenschlager C.   Neef H.   Silber R.E.  

European Journal of Cardio-Thoracic Surgery, Vol. 21, Iss. 4, 2002-04 ,pp. : 606-610

Elsevier

Access to resources Recommend Favorite